Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

Objectives/Hypothesis: Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)-4/IL-13 receptor component, significantly improved outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the SINUS-24 and SINUS-52 studies. This post hoc analysis eva...

Full description

Bibliographic Details
Main Authors: Amin, N. (Author), Bachert, C. (Author), Chuang, C.-C (Author), Daizadeh, N. (Author), Duverger, N. (Author), Fan, C. (Author), Fokkens, W.J (Author), Guillemin, I. (Author), Hellings, P.W (Author), Kamat, S. (Author), Khan, A.H (Author), Lee, S.E (Author), Mannent, L.P (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2022
Subjects:
adult
Adult
aged
Aged
anosmia
Antibodies, Monoclonal, Humanized
Article
chronic disease
Chronic Disease
chronic rhinosinusitis
clinical trial
complication
computer assisted tomography
controlled study
corticosteroid
disease severity
double blind procedure
Double-Blind Method
drug efficacy
dupilumab
female
Female
human
Humans
major clinical study
male
Male
middle aged
Middle Aged
monoclonal antibody
multicenter study
Nasal Polyps
nose obstruction
nose polyp
odor recognition test
paranasal sinus
Patient Reported Outcome Measures
patient-reported outcome
Pennsylvania
placebo
quality of life
randomized controlled trial
respiratory tract disease assessment
rhinitis
Rhinitis
rhinorrhea
sinusitis
Sinusitis
treatment outcome
Treatment Outcome
treatment response
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items